Retatrutide (GLP-3)
Retatrutide (LY3437943) is a next-generation peptide and the first triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. Within research, Retatrutide is being intensively studied for its notable effects on weight regulation, glucose metabolism, and lipid profile in preclinical models.
- Sent from the Netherlands
- Delivery to pickup point available
- Discreet shipping
Description
Description
Retatrutide is an advanced investigational peptide that receives significant attention within scientific and preclinical contexts due to its triple receptor profile. This investigational compound is being investigated for its interaction with GLP-1, GIP, and glucagon receptors and is therefore an interesting subject in contemporary metabolic research.
In our research catalog, Retatrutide is intended for professionals who value clear product specifications, a polished presentation, and discreet handling. Ideal for research environments where consistency, product information, and reliable sourcing are paramount.
Important: intended exclusively for research use only. Not for human consumption, diagnostic, or therapeutic use. Retatrutide is an investigational molecule and is only legally available within clinical studies.
Retatrutide lyophilized powder (>99% purity) in a 3 ml bottle. Requires reconstitution with a solvent such as BAC Water
Additional information
Additional information
| Name | Retatrutide |
|---|---|
| Type | Research Peptide: Triple Hormone Receptor Agonist (GLP-1/ GIP/ GCGR) |
| Concentration (mg) | 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg |
| Purity | ± 99% (HPLC – COA available) |
| Form | Lyophilized powder |
Usage and disclaimer
- Intended solely for research purposes.
- Not intended for human use, diagnosis, or treatment.
- Only for qualified personnel in a controlled research environment.
- By purchasing this product, you confirm that you have read these Terms of Use and agree to standard research practices.
Related products
SLU-PP-332
